Angiogenesis is required for tumor growth and metastasis, and targeting angiogenesis is a novel anti-cancer strategy. However, cancer development is a complex multistep process, single anti-angiogenic agents have limited therapeutic efficacy. Here, we report a triple fusion protein, namely CTT peptide-endostatin mimic-kringle 5 (AARP), consisting of MMP-2/9 selective inhibitory peptide (CTT peptide) and well-known endogenous anti-angiogenic agents (endostatin mimic, kringle 5), which can simultaneously target matrix metalloproteinases (MMPs) and endothelial cells, blocking their actions. AARP was bacterially expressed, and biological activity of purified AARP was assessed. AARP could significantly inhibit the enzymatic activity of MMP-2/9, proliferation, migration and tube formation of endothelial cells in vitro. The antitumor activity of AARP was shown in a concentration-dependent manner when injected i.p. into immunodeficient mice bearing multi-drug resistant human KB epidermoid carcinomas, and AARP is superior to clinical grade endostatin in inhibiting KB xenograft growth. In mouse models of Lewis lung carcinoma (LLC) and hepatoma H22, when given as a single dose, AARP is highly effective for reducing tumor growth, angiogenesis, metastasis, and increasing survival time. AARP possessed significantly greater anti-angiogenic activity than endostatin mimic, CTT peptide-kringle 5 (RK5) both in vitro and in vivo. Compared with conventional chemotherapeutic agents (cyclophosphamide and paclitaxol), AARP is also effective. More importantly, AARP is cytocompatible and no tissue toxicity could be observed after large dose administration. Taken together, our findings suggest AARP is a highly effective, safe and more potent antiangiogenic agent for blocking tumor angiogenesis, metastasis, and warrant further testing for clinical applications.
Introduction
block redundancies in tumor angiogenesis regulators (21, 22) . Therefore, the development of multi-targeted antiangiogenic agent is needed for tackling these challenges and arises as an attractive therapeutic approach to treat cancer and other angiogenesis-dependent diseases (22) .
Here, we report a novel triple fusion anti-angiogenic protein, AARP, consisting of endostatin mimic (NH 2 -terminal 25-amino-acid peptide of endostatin), an MMP-2/9 selective inhibitory peptide (CTTHWGFTLC), and kringle 5 fragment of human plasminogen (7, 12, 23) . We reasoned that this triple fusion protein would increase the half-life of endostatin mimic peptide, enhance antiangiogenic activity of RK5 (CTT peptide-kringle 5) or endostatin mimic peptide. We produced this novel fusion protein in Escherichia coli and described the antitumor activity in vitro and in vivo. We showed that this triple fusion protein have significantly enhanced antiangiogenic and antitumor efficacy in several cancer models. More importantly, compared with conventional chemotherapeutic agents such as paclitaxol and cyclophosphamide, AARP is also effective without detectable toxicity. Our findings indicate that this triple fusion protein AARP may be a promising agent for anti-angiogenic therapy of cancer.
Materials and Methods
Detailed methodology is described in the Supplementary data.
Cell Lines and Animals
Lewis lung cancer cell line LL/2, murine hepatoma cell line H22, non-endothelial cells (293T, HepG2, HT1080, HeLa, HCT116, RAW264.7, THP-1, U937) were purchased from the American Type Culture Center (ATCC). Theses cell lines were authenticated using PCR fingerprinting by the provider. Human multi-drug resistant KB epidermoid carcinoma cells were kindly provided by professor Li-Wu Fu from the Sun Yat-sen University (GuangZhou, China). The human KB cells were were authenticated by short tandem repeat (STR)-profiling (Promega Powerplex® 16 System). KB cells, 293T, HepG2, HT1080, HeLa, HCT116 cells were grown in DMEM (Invitrogen) supplemented with 10% FBS (GIBCO) and 1% Penicillin-Streptomycin (GIBCO). LLC cells, H22 cells, RAW264.7, THP-1, U937 cells were grown in complete RPMI 1640 (Invitrogen) supplemented with 10% FBS. Human umbilical vein endothelial cells (HUVEC) were kindly provided by Dr. Jincai Luo (PeKing university, China), which were isolated from umbilical cord vein following collagenase digestion (24) . HUVEC were maintained in M199 with 2 mM l-glutamine, 20% FBS , 3 ng/ml bFGF, 1% Penicillin-Streptomycin, were used at passage [2] [3] [4] [5] [6] . No authentication of the HUVEC were done by our authors. All cells were maintained and propagated at 37℃ in a humidified 5% CO 2 incubator. All cells were passaged for less than 6 months in our laboratory after receipt or resuscitation.
Male athymic Balb/c nude mice (nu/nu), Balb/c mice, Kunming mice, C57BL/6 mice (6-8 weeks) were purchased from Beijing Vital River Laboratories. All animal experiments were done in compliance with the guidelines approved by the Institutional Animal Care and Use Committees of PeKing University and the mice were maintained in accordance with the guidelines for the care and use of laboratory animals.
Construction, expression, and characterization of RK5, AARP RK5 was expressed and purifed according to Zou et al (25) . cDNA encoding triple fusion protein AARPαand isoform AARPβwere amplified with overlap extension PCR. cDNA sequence encoding 25 aa of N-terminal endostatin and CTT-peptide (10 aa) were connected to kringle 5 cDNA, 25aa/10 aa/ kringle 5 were connected with a flexible peptide linker. AARPαand AARPβwere expressed in E. coli BL21 (DE3) cells by 1 mmol/L isopropyl-1-thio-β-galactopyranoside (IPTG) induction 16 h at 25°C. The isolated inclusion bodies are solubilized in 8 M urea, and the target proteins were purified and refolded.
Cell Proliferation analysis
HUVECs were maintained in M199 containing 20% heat-inactivated fetal bovine serum (FBS; GIBCO) and recombinant human basic FGF (3 ng/ml). Cells were dispersed in 0.05% trypsin solution, resuspended with M199 containing 1% FBS, and seeded in each well of 24-well plates (1×10 4 cells in 0.5 ml per well, counted with a hemocytometer). After adherence (4-6 hr), the medium was replaced with 0.1% FBS containing test proteins (25 aa, RK5, AARP α , AARP β ). 72h later, HUVEC proliferation was measured by MTT colorimetric assay (n=4 independent experiments).
Cell migration assay
Cell migration assay was performed using a transwell system (Costar, Corning, USA), which allows cells to migrate throughout an 8-mm pore size polycarbonate membrane of millicell (matrigel-coated transwells). HUVEC cells were plated (10 4 cells/well) into upper chamber in M199 containing 0.1% FBS, and 1.5 μM of 25aa, RK5, 25aa+RK5, AARPα, AARPβ or PBS) were added in the lower chamber of a 24-well plate containing 20% FBS, 20 ng/ml VEGF, 20 ng/ml bFGF. After 48 h, cells remaining on the upper surface of the membrane were scraped and the cells on the lower surface of the membrane were fixed with cold methanol for 30 min and stained with 0.2% crystal violet. Cells that had migrated to the bottom of the membrane were visualized and counted (n=4 independent experiments).
Tube formation assay.
A 48-well plate coated with 0.2 ml matrigel (10mg/ml, BD Biosciences) per well was allowed to solidify at 37℃ for 1 h. Each well was seeded with 1×10 4 previously starved HUVEC and cultured in M199 containing 20 ng/ml VEGF+20 ng/ml bFGF in the presence of tested substances (1.5 μM of 25aa, RK5, 25aa+RK5, AARPα, AARPβ or PBS) for 48 h. The networks of tubes were photographed and relative lengths were compared (n=4 independent experiments).
In vitro β-casein degradation assay.
MMP-2 (50-100 ng, Sigma) was preincubated for 60 min with RK5, AARPαand
AARPβat concentrations indicated in the text. The substrates, a 21 kDa β-casein (52 μM) was incubated for 1 or 2 h at 22℃ (the total reaction volume was 10～15μl).
Degradation of β-casein was analyzed by SDS gel electrophoresis essentially as described (23) .
Hemolytic assay
Erythrocytes were washed with PBS until the supernatant was clear and then resuspended in PBS. Erythrocyte suspensions (1×10 7 cells/mL) were incubated with 25 μM of different proteins (kringle 5, RK5, AARPαand AARPβ) at 37℃ for 30 minutes and then centrifuged at 1000 g for 5 minutes at 4℃ to precipitate intact erythrocytes and debris. The supernatants were assayed for absorbance at 570 nm to determine the amount of hemoglobin released from the lysed erythrocytes. The absorbance of a supernatant obtained using 0.1% Triton X-100 was used as positive control. The supernatant of an untreated erythrocyte suspension in PBS was used as a spectrophotometric blank.
Pharmokinetics and toxicity analysis of AARPα
For in vivo pharmacokinetics study, 21 Balb/c mice (7 mice each group) were were intravenously injected with 125 I-AARα, 125 I-25 aa, 125 I-RK5 at a single dose of 5 mg/kg. The γ-counter was used to detect the radioactivities of all samples. The concentration of AARPαat each time points was used to determine its blood clearance rates. The distribution data were expressed as percentage of the injected dose per gram of tissue (%ID/g).
The hemolytic activity of purified proteins (kringle 5, RK5, AARPαand AARPβ)
were determined using human erythrocytes, as previously reported (26) .
To evaluate the toxicity effect of AARPα, mice were treated with normal saline or 
Mouse Tumor Models Human xenograft model
Multi-drug resistant human KB epidermoid carcinoma cells were grown and maintained in DMEM medium supplemented with 10% FBS and antibiotics. The KB cell concentration was adjusted to 1×10 7 cells/mL. A suspension of 1× 10 6 tumor cells in 0.1 mL DMEM containing thawed matrigel (1:1) was injected s.c. into the dorsal back of athymic Balb/c nude mice (n=12-14 per group) at the proximal midline. At the completion of this experiment, the mice were euthanized with CO 2 inhalation. Syngeneic xenograft models LLC (Lewis lung carcinoma, syngeneic with the C57BL/6 mouse strain) cells were propagated by sequential subcutaneous transplantion in C57BL/6 mice. Tumor cells were prepared by mincing the tumor, cells were sieved through a 300 mesh stainless steel, then thoroughly washed with PBS to remove erythrocytes. The viability (>85%) of the tumor cells was determined by trypan blue exclusion. Then 1×10 6 LLC cells in 0.1 mL of PBS via a 29-guage needle were injected subcutaneously into the dorsal back of each mouse (mice were shaved 1 day before injection, n=20-23 per group).
Murine H22 hepatoma cells (syngeneic with the Balb/c mouse strain) were passaged in the ascites of Kunming mice. After 8 days, the intraperitoneal tumor cells were collected from the mouse with ascites tumor. Viable tumor cells were counted by trypan blue staining (>85% viability); next, 5×10 6 murine H22 hepatoma cells in 0.1 mL of PBS via a 29-guage needle were injected subcutaneously into the dorsal back of each mouse (mice were shaved 1 day before injection, n=20-23 per group).
For treatment of tumor-bearing mice, when solid tumors were visible (tumor volumes were allowed to grow to 15∼30 mm 3 , average tumor volume >20 mm 3 ), and mice were randomized into indicated groups, and the treatments were carried out. The mice were given intraperitoneal injections of clinical grade endostatin, endostatin mimic (25 aa), RK5, AARPα, AARPβ,clinical grade cyclophosphamide (KB human xenograft), or paclitaxol (LLC and H22 syngeneic xenograft) (indicated dose, frequency, and duration). As a control, an equal volume of saline was injected in the same manner. The tumor weight, tumor volume of each mouse (KB xenograft) was recorded 3-6 days. The body weight, survival rate of each mouse (LLC and H22) was recorded, and longitudinal tumor volume was calculated from caliper measurements using volume=(length) ×(width) 2 (27) . Six days later, mice were randomized into 4 groups, and treatments initiated. The mice were given intraperitoneal injections of RK5, AARPα, AARPβ(indicated dose, frequency, and duration). As a control, an equal volume of saline was injected in the same manner. Mice were sacrificed by CO 2 inhalation for examination at 28 days, after tumor inoculation. Metastases were assessed by gross necropsy, macroscopic pictures of lungs were taken and metastatic nodules (>200μm) were counted for each lobe using a dissecting microscope at 4× magnification.
Immunohistochemistry analysis
Following standard antigen retrieval protocol, CD31 antibody (Abcam) was used to stain formalin-fixed, paraffin-embedded sections at a 1:500 dilution for 1 hour at room temperature. Slides were again rinsed and then incubated with horseradish peroxidase (HRP) conjugate of goat anti-mouse IgG (Santa Cruz) at a 1:200 dilution for 30 minutes at room temperature. Slides were then rinsed and incubated with DAB (DAKO Cytomation K3468). Slides were rinsed and dehydrated through a series of ascending concentrations of ethanol and xylene and then coverslipped. The CD31/MVD expression was determined in photomicrographs of tumor tissues (n=5) with total ×100 magnification in 3 fields from area of highest vascular density in the tumor per slide. Vessels up to 50 µm in diameter were considered for counting.
Statistical analyses.
Results are depicted as the mean ± SEM. Statistical analyses were performed using Student's t test. GraphPad Prism (v. 5, GraphPad) was used for statistical analysis. Multiparameter statistics for the Kaplan-Meier survival curves were performed by a log-rank test. All statistical tests were 2-sided, with P<0.05 considered significant.
Results

Characterization and preparation of AARPα and AARPβ
The chimeric protein AARP ( Figure. 1A) is composed of CTT peptide (an MMP-2/9 inhibitory peptide, CTTHWGFTLC), endostatin mimic (N terminal 25 amino acids of the native molecule) and kringle 5 fragment of plasminogen (7, 12, 23) . AARP represents anti-angiogenic recombinant protein. RK5 is a double fusion protein we previously developed, which contains CTT peptide and kringle 5 (25) . There could be two variants of triple fusion protein when 25 aa fused with RK5 as illustrated in proteins, mainly existing in inclusion bodies, were solubilized with 8 mol/L urea and purified by Ni 2+ chelate affinity chromatography under denaturing conditions. The proteins were then refolded by dialysis against gradually decreased urea concentrations (from 4 to 2 mol/L) and finally in PBS (pH 7.4) (10, 28, 29) . RK5 showed an apparent molecular weight of 12 kDa, AARPα and AARPβ showed an apparent molecular weight of 15 kDa, matching the calculated molecular weight based on the sequence (Figure.1B) . The purity of the target proteins reached >90%, and the integrity of RK5, AARPα and AARP β were further determined with N-terminal sequencing.
AARP is more potent in inhibiting endothelial cell proliferation, migration and tube formation
The CTT peptide (CTTHWGFTLC) is a potent and selective inhibitor for matrix metalloproteinases MMP-2 and MMP-9, which was found by phage-display technology (23) . Importantly, synthetic and recombinant CTT peptides showed nearly identical inhibitory activities against MMP-2 and MMP-9 (25, (30) (31) (32) (33) . In our previous study, we found recombinant CTT peptide, when fused with kringle 5, could inhibit MMP-9 caseinolytic activity in a concentration-dependent manner (25) . In the currect report, we initially investigated whether recombinant CTT peptide, when fused with 25 aa and kringle 5, could retain potent MMP-2/9 inhibitory activity. The inhibitory activities of CTT peptide-endostatin mimic (25 aa)-kringle 5 (namely AARPα) and endostatin mimic-CTT peptide-kringle 5 (namely AARPβ) toward MMP-2/9 were examined by casein degradation assay. As shown in Figure. 1C and Figure S1 , the degradation of casein by MMP-2/9 was prevented in the presence of RK5, AARPα and AARPβ at a dose-dependent manner, the results of the MMP-2/9 inhibition study were consistent with those previously described (23) .
Next, we evaluated the effect of AARPα and AARPβ on the proliferation of endothelial cells. MTT assay showed that both AARPα and AARPβ are much more potent in inhibiting HUVEC proliferation than RK5 alone and RK5+25aa in a dose-dependent manner (p<0.01), indicating the triple fusion protein (AARPα/AARPβ) is more effective than the additive inhibitory efficacy of 25aa plus RK5 ( Figure.1D ). RK5, AARPα/AARPβ appeared to be endothelial cell specific because macrophage-derived cells and tumor cells were completely insensitive to RK5, AARPα/AARPβ treatments at the concentration required for maximal inhibition of HUVEC cell proliferation (>1.5 μM) as compared with nontreated cells (Figure. To further compare the antiangiogenic efficacy of AARPα/AARPβ with that of RK5, We next tested the effect of these recombinant proteins on HUVEC migration and tube formation. AARPα and AARPβ inhibited the HUVEC migration and tube formation much more effectively than RK5 at the concentration of 1.5 μM. However, an additive inhibitory efficacy of RK5 plus 25 aa, was detected when RK5 and 25 aa (1.5 μM) were added together to HUVEC cells. Interestingly, this additive inhibitory efficacy is inferior to that produced by AARPα or AARPβ alone, and no statistically significant difference has been found between AARPα and AARPβ ( Figure. 2A, B) . We chose AARPα, hereafter referred to as AARP, as the best candidate.
Pharmacokinetics and Potential Toxicity of AARP
The pharmacokinetic profiles of I 125 labeled 25 aa, RK5 amd AARPα (5 mg/kg)
were evaluated in Balb/c mice following single intravenous adminstration. After harvesting blood samples, drug concentration was quantified with a survey meter (Geiger counter). The pharmacokinetic profiles showed that the half life of AARPα (≈13.1 hr) was longer than that of RK5 (≈9.4 hr) and 25 aa (<2 hr) ( Figure. 3A) . Hemolysis of red blood cells (RBCs) is another problem associated with the bio-incompatibility of a material. We examined the potential hemolytic activity of 25aa, RK5, AARPα and AARPβ (25 μM) by measuring supernatant absorbance at 570 nm, positive control was Triton X-100 (0.1% v/v), a known hemolytic agent. As shown in Figure 3B , 25aa, RK5, AARPα and AARPβ exhibited negligible hemolysis degrees in comparison with the control Triton X-100.
Furthermore, we examined the potential toxicity of high dosage of AARPα in Balb/c mice (250 mg/kg of body weight, intraperitoneal administrated every day for 32 days), PBS served as normal control. During the treatment period, no significant differences in body weight change were observed in saline and AARPα treated group ( Figure. 3C ). Mice treeated with saline and AARPα were sacrificed at the end of the 32 day treatment period, blood samples were collected. Serum biochemical parameters, including aspartate aminotransferase (AST), aspartate aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine (Cr) were evaluated. Kidneys, lungs and livers were collected for pathological examination. AST, ALT, BUN, and creatinine levels in AARPα-treated mice were all within the normal range ( Figure.  S4) . No gross histological signs of toxicity were observed in AARPα treated mice ( Figure. 3D) , indicating that treatment with AARPα produced virtually no toxicity or nondetectable toxicity in mice.
AARP has significant in vivo antitumor activity against KB xenografts
To explore the value of AARPα as an anti-angiogenic therapeutic molecule, we first evaluated the effect of AARPα on tumor growth in vivo. We implanted 1×10 6 multi-drug resistant human epidermoid carcinoma KB cells subcutaneously into dorsal back of immunodeficient mice, the mice were left for 6 days, allowing a small nodule (>20 mm 3 ) to grow and mice were randomly grouped into 6 groups. The mice received intraperitoneal injection (i.p) of 10, 20, and 40 mg/kg of AARPα, 10 mg/kg 
clinical grade endostatin (produced and approved in China), equivalent amount of saline (as a control) every other day, 100 mg/kg clinical grade cyclophosphamide (i.p injected every 5 days) for the subsequent 30 days, and the tumor growth was measured every 4-6 days. Compared to normal saline and endostatin treatment, tumor growth was markedly attenuated with AARPα and cyclophosphamide treatment ( Figure. 4A) .Treatment with AARPα significantly reduced tumor growth and tumor weight in mouse xenograft models of KB in a concentration dependent manner, whereas no distinct differences were observed between 10 mg/kg AARPα-and endostatin-treated groups ( Figure. 4A) . Because 20-40 mg/kg AARPα administration exerted strong inhibitory effect in tumor growth, we chose this dosage range for subsequent experiments.
AARP is highly effective in reducing tumor growth, metastasis, and extending mouse survival in LLC implantation model
We generated a LLC model by implanting 1×10 6 LLC cells into subcutaneous dorsal back of C57BL/6J mice. Six days later, the mice received intraperitoneal injections of 25 mg/kg RK5, AARPα, AARPβ, equal amount of normal saline and 10 mg/kg of paclitaxol every day for the subsequent 22 days and the tumors were sampled. In LLC tumor model, the tumor growths were significantly attenuated by AARPα and AARPβ compared with RK5 treatment (Figure. 5A, B) . Kaplan-Meier survival analysis showed that mice treated with AARPα and AARPβ lived significantly longer than RK5 treated mice (p<0.01) (Figure. 5C ). The toxicity of RK5, AARPα and AARPβ treatment was evaluated by observing the body weight, and no apparent weight loss was observed. While paclitaxol treatment resulted significant toxic side effects evidenced by significant weight loss ( Figure. S5 ). Then, we tested the effects of RK5, AARPα and AARPβ on the histological structure of LLC tumors. In comparison with normal saline treatment, RK5, AARPα and AARPβ treatment significantly reduced tumor blood vessel densities as demonstrated by CD-31 immunostaining. Importantly, AARPα and AARPβ treated tumors showed less tumor blood vessel densities than RK5 ( Figure. 5D ) (**p<0.01).
As tumor metastasis is also angiogenesis dependent, an experimental lung metastasis model was generated to evaluate whether RK5, AARPα and AARPβ could also inhibit growth of metastatic nodules. LLC cells were intravenously injected into the tail vein and allowed to circulate for 6 days, then treatments initiated. After 22 d of treatments, mice were autopsied for metastatic analysis. RK5, AARPα and AARPβ treatment dramatically reduced development of lung metastatic nodules. All saline treated mice had enlarged lung and macroscopic malignant nodules. In contrast, the median numbers of macroscopic metastases (>200 μm) in lung were significantly lower in AARPα and AARPβ-treated mice than RK5 treatment group ( Figure. 5E ) (**p<0.01).
AARP exerts markedly greater effects than RK5 and 25 aa in implanted H22 hepatocarcinoma model
We performed additional experiments to assess the effects of 25aa, RK5, AARPα, 1% (Figure. 6A) . Corresponding survival curves showed significantly increased median survival in RK5, AARPα and AARPβ treatment group when compared to controls, and group AARPα and AARPβ significantly prolonged overall survival than group RK5 and 25aa ( Figure. 6B ) (**p<0.01). During the treatment course, no significant (p>0.05) difference in body weight was observed between 25 aa, RK5, AARPα, AARPβand control group, whereas paclitaxol treatment caused significant weight loss (Figure. 
Discussion
The angiogenic switch, a rate-limiting step in tumor progression, has already occurred by the time most human tumors are detectable. The angiogenic switch is not limited at earliest stages, but occurs also at different stages of tumor-progression (2). Anti-angiogenic therapy is a promising alternative for treatment of cancer, and may also be used as a maintenance therapy to prevent the metastasis or recurrence (3). Therapy with endogenous angiogenic inhibitors such as endostatin and angiostatin may reverse the angiogenic switch by preventing growth of tumor vasculature. Angiostatin can maintain metastases in a dormant state in laboratory animals when administered exogenously (34) . In transgenic mice overexpressing endostatin, a small increase of circulating endostatin (approximately 1.6-fold) is sufficient to confer dramatic protection against tumor growth (11) . In individuals with Down syndrome, a similar small increase of circulating endostatin is associated with a remarkably low incidence of solid tumors (35) . These suggest that modest but sustained increases in angiogenic inhibitors (angiostatin or endostatin) may be capable of significantly inhibiting tumor growth.
Peptides have emerged as important therapeutics that is rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity (36) . Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin), several peptides (including endostatin mimics and gelatinase inhibitory peptide CTTHWGFTLC) have shown promise in pre-clinical and clinical studies for cancer (23, 37) . Angiogenesis inhibitors, particularly polypeptides or endogenous peptides, may become the safest and least toxic therapy for diseases associated with abnormal angiogenesis (36, 37) . However, the use of peptides in vivo has largely been limited by their extremely short half-life. Therefore, increasing the in vivo residence times of peptide therapeutics could decrease their dosing frequencies. Several strategies have been employed to improve the half-life of biological peptides including fusion or conjugation to immunoglobulins and serum proteins, incorporation into the drug delivery vehicles, and conjugating to natural or synthetic macromolecules (38) .
Thus, when developing therapeutic antiangiogenic proteins, the efficacy, half-life, bioavailability, molecular size, stability and effectiveness should be considered. To fulfill these considerations, we developed an elegant triple fusion protein, AARPα. AARPα is a chimeric protein consisting of a MMP-2/9 selective inhibitory peptide (CTTHWGFTLC), endostatin mimic (NH 2 terminal 25 amino acids of endostatin), kringle 5 fragment of human plasminogen. Our results showed that AARPα and its isoform AARPβ are more potent than RK5 (which lacks 25 aa) in suppressing endothelial cell activation (proliferation, migration, tube formation). Interestingly, the biological activity of AARPα and AARPβ are more potent than that of RK5 plus 25 aa, indicating CTT peptide, endostatin mimic, kringle 5 have synergistic effect when fused into a single molecule. Bioavailability is of paramount importance in the systemic use of bioactive molecules and developing therapeutic proteins. AARPα has relatively high bioavailability and a longer half-life (half life ≈13.1 hours), raising the possibility that AARPα could be a superior therapeutic protein to endostatin (half life ≈2 hours), angiostatin (half life ≈15 minutes) and RK5 (half life ≈9.4 hours), assuming that it retained its ability to simultaneously inhibit the growth and migration of endothelial cells (12, 39) . The results of hemolytic effect on human erythrocytes showed that AARPα and AARPβ are cytocompatible. Furthermore, repeated administration of large amount of AARPα (250 mg/kg, once daily for 32 days) didn't induce anticipated toxicities such as weight loss, abnormal serum biochemical parameters and main organ damage, indicating AARPα is safe without any detectable toxicity.
In the current research, we employed three preclinical cancer models, multi-drug resistant human epidermoid carcinoma xenograft model, and two murine allografts (Lewis Lung carcinoma and H22 allografts), which are angiogenesis dependent and have been widely used to test the activity of anticancer agents. In multi-drug resistant human epidermoid KB carcinoma xenograft model, intraperitoneally administered AARPα showed more potent antitumor effects. The effect on KB xenograft growth was dose dependent, a dose of 10 mg/kg AARPα was more effective than 10 mg/kg of clinical grade endostatin every other day, and 40 mg/kg (every other day) was comparable to 100 mg/kg cyclophosphamide (given every 5 days). Endostatin therapy alone did not have a significant anti-tumor effect on multi-drug resistant human epidermoid carcinoma xenografts, its anti-tumor effect might be compromised by lower molar concentration and a short half life.The theoretical molar concentration of 10 mg/kg AARPα (Mw=15 kD) is 16.66 μM, while for 10 mg/kg clinical grade endostatin (Mw=21 kD), the theoretical molar concentration is 9.09 μM. The half life of clinical grade endostatin is less than 2 hours, while the half life of AARPα is 13.1 hours. Thus, it seems plausible that AARPα has more prounced antitumor effect than endostatin.
China accounts for almost 50% of the world's liver cancer cases, accounts for one-third of global deaths from lung cancer, and developing drugs in cancer therapy is imperative than ever before. We further evaluated the anti-tumor effect of AARP in two murine syngeneic models (Lewis Lung carcinoma and H22 hepatoma xenograft). Superior antitumor effect and survival promoting effect of AARP were observed with LLC and H22 tumors, confirming the broad biological effect of AARP. Immunohistochemical studies carried out on LLC and H22 tumor tissues showed AARPα and its isoform AARPβ could significantly reduce tumor angiogenesis. One of the most important effects of AARP is the prevention of lung metastasis in mice. Metastatic tumors are very common in the late stages of cancer and is often associated with a poor prognosis and survival rate. Expansion of metastatic lesions are also angiogenesis dependent. Our results showed that AARP is more potent in suppressing lung metastasis than RK5. In this report, we also compared the anti-tumor effects of paclitaxol and RK5, AARPα/AARPβ. Our results showed that paclitaxol was more effective than anti-angiogenic inhibitors (RK5, AARPα/AARPβ). The paclitaxol dose was 10 mg/kg, the doses for RK5, AARPα/AARPβ were 25 mg/kg. But when doses were converted to molar concentration, we found the molar concentration for paclitaxol was 117.1 μM, whereas the molar concentration for RK5, AARPα/AARPβ were 16.66 μM. It's perhaps not surprising that the antitumor effect of paclitaxol is more pronounced than that for RK5, AARPα/AARPβ. But compared with saline treatment, the RK5, AARPα/AARPβ still exerted very significant anti-tumor effects.
Tumor induced sprouting angiogenesis involves remodeling of cell-cell junctions and extracellular matrix (in part by MMPs), endothelial cell proliferation, migration, and lumen formation (2) . The specialization of quiescent endothelial cells into migrating tip cells and proliferating stalk cells is a key event during sprouting angiogenesis (40) . From a therapeutic viewpoint, strategies targeting endothelial cells (tip and stalk cells) that line tumor infiltrating blood vessels would prevent neoangiogenesis, and cause vessel regression (41) . Based on our results, AARP not only retains the biological activity of kringle 5, CTT peptide and endostatin, but is more potent than each single agent alone in inhibiting endothelial cell growth, migration, tube formation and tumor angiogenesis. Therefore, we hypothesize that AARP is a versatile, broad-spectrum anti-angiogenic molecule which could target both endothelial phenotypes. But the exact downstream signaling of AARP in endothelial cell proliferation, migration, tube formation remains to be further elucidated, then clinical trials can be done in the correct context, the right tumor types, 
and thus in patients that will benefit the most.
Since Dr. Judah Folkman first proposed the hypothesis that tumor growth is angiogenesis dependent and suggested that tumour dormancy could be maintained by preventing neovascularization of microscopic cancers, antiangiogenic therapy has been an attractive target for cancer therapy and increasingly validated in various preclinical cancer models (42) . However, to date, pre-clinical and clinical studies evaluating the therapeutic potential of various targeted antiangiogenic agents have reported conflicting results, generating controversy (43, 44) . The crux of clinical validation of antiangiogenic therapy lies cancer is still usually treated at advanced, often metastatic, disease stages (45) . In the setting of heavy disease burden, most patients treated with antiangiogenic agents eventually experience disease progression due to evolution of biological escape mechanisms by tumours (46, 47) . What has emerged from our work is that the utility of tumor angiogenesis inhibition in the clinic should be tumor context dependent. We propose that tumor type, stage, microenvironment, and maybe even age of the patient will be major contributors to the outcome of therapy. It could be argued that the clinical benefit and impact would be greater if the therapy were initiated at earlier stages of malignancy, with the aim of keeping them in a dormant state by preventing the angiogenic switch. This would result in a substantial reduction in the cancer incidence or cancer recurrence risk. However, lengthy clinical trials will be required to test this hypothesis.
The use of multi-targeted anti-angiogenic agent such as AARP is an appealing approach targeting nonmalignant endothelial cells that form the tumor vasculature and indirectly affects tumor cells thus minimizing the risk of toxicity (22) . A gram of tumor has been estimated to contain ~10 8 -10 9 tumor cells, and the ratio of endothelial cells to tumor cell is in the range of 1/10 to 1/100 (19) . This means that endothelial cell-targeted therapies have a built-in amplification in that a relatively small insult to the vascular endothelium induces vascular failure and extensive ischemic necrosis results. The problem of drug resistance associated with conventional chemotherapy agents is avoided because normal endothelial are genetically stable unlike tumor cells (4) . Endothelial cells form a continuum throughout the circulation and all endothelial cells are in direct contact with the blood, which makes them are readily accessed by therapeutic drugs delivered intravenously (18, 19) . More inportantly, endothelial cells in new vessels are vulnerable to therapeutic attack compared to mature, quiescent, and protected ECs in the established vasculature (18) (19) (20) . In addition, as a multi-target angiogenesis inhibitor, chimeric protein AARP can be more efficacious and can act synergistically with current chemotherapies, radiation and gene therapies (48).
There could be possible shortcomings of AARP. The clinical relevancy of AARP may be limited due to the use of xenograft models. Since subcutaneous xenograft models do not faithfully recapitulate the clinical, pathologic, genetic and molecular aspects of human tumors, which may affect the results when comparing therapy responses between pre-clinical mouse models and cancer patients (49). However, to overcome the limitations of the xenograft model, we used syngeneic mouse model (H22, LLC carcinoma) to evaluate the anti-angiogenic efficacy of AARP, the immune system is not compromised, and thus it may more closely mimic the tumor micro-environment in patients. Additionally, in three tumor models, we used conventional chemotherapeutic agents (cyclophoshamide and paclitaxol) to test the reliability, robustness of established tumor xenograft models and evaluate the anti-angiogenic efficacy of AARP. Certain tumor types can also employ non-sprouting modes of angiogenesis, including intussusceptive angiogenesis, vasculogenic mimicry, vessel co-option, recruitment of endothelial progenitor cells, and cancer stem-like cell derived vasculogenesis (40, 50) . Non-sprouting angiogenesis may operate in parallel with sprouting angiogenesis. These noncanonical mechanisms of angiogenesis may provide blood supply before induction of the angiogenic switch, or occur as an adaptive response to changes in the tumor environment. However, we believe our findings clearly indicate that tumor angiogenesis is mainly dependent on sprouting angiogenesis in the tumors we studied. Therefore, the application of AARP deserves to be diversified to various tumor models (i.e., orthotopic and genetically engineered mouse models) to determine the possible benefits and effectiveness over other anti-angiogenic agents.
In summary, AARP shows promising therapeutic properties in the treatment of solid tumors and metastasis in mice, while possess no side effects. Because recombinant AARP protein is fully humanized, stable, and selectively cytotoxic to tumor associated endothelial cells and can be produced in large amounts. We propose that the simultaneous inhibition of MMP-2/9, endothelial cell growth and migration by AARP can be a reasonable candidate therapeutic protein for cancer maintenance therapy, metastasis, and further preclinical studies are warranted to explore additional applications of AARP for the treatment of cancer.
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